These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 37489138)

  • 21. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
    Ye C; Zheng L; Yuan CH
    Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human microbiota colonization and pancreatic ductal carcinoma.
    Fang Y; Yang G; Yang J; Ren J; You L; Zhao Y
    Crit Rev Microbiol; 2023 Aug; 49(4):455-468. PubMed ID: 35924947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
    Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
    Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in oncolytic adenovirus therapy for pancreatic cancer.
    Nattress CB; Halldén G
    Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma.
    Sarfraz H; Saha A; Jhaveri K; Kim DW
    Curr Oncol; 2023 May; 30(6):5322-5336. PubMed ID: 37366887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.
    Brind'Amour A; Webb M; Parapini M; Sidéris L; Segedi M; Chung SW; Chartier-Plante S; Dubé P; Scudamore CH; Kim PTW
    Clin Exp Metastasis; 2021 Apr; 38(2):187-196. PubMed ID: 33486670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
    Haller SD; Monaco ML; Essani K
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
    Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of epigenetics in pancreatic ductal adenocarcinoma.
    Pandey S; Gupta VK; Lavania SP
    Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
    Adiseshaiah PP; Crist RM; Hook SS; McNeil SE
    Nat Rev Clin Oncol; 2016 Dec; 13(12):750-765. PubMed ID: 27531700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Status of Immunotherapies for Treating Pancreatic Cancer.
    Wu AA; Jaffee E; Lee V
    Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biological underpinnings of therapeutic resistance in pancreatic cancer.
    Beatty GL; Werba G; Lyssiotis CA; Simeone DM
    Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy.
    Al-Share B; Hammad N; Diab M
    Cancer Metastasis Rev; 2021 Mar; 40(1):355-371. PubMed ID: 33398620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects.
    Polani F; Grierson PM; Lim KH
    World J Gastroenterol; 2021 May; 27(18):2105-2121. PubMed ID: 34025067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in pancreatic cancer treatment.
    Krug S; Michl P
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):427-43. PubMed ID: 23207616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.